Keytruda 395 mg oplossing voor injectie
As listed in the register: Keytruda 395 mg oplossing voor injectie
395 mg · oplossing voor injectie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Pembrolizumab
- Made by
- MSD Europe Belgium SRL
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (KEYTRUDA). It describes the substance, not this exact product.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production.
Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-10
Safety of the active substance
From the US prescribing label for the same active substance (KEYTRUDA). It describes the substance, not this exact product.
Most common adverse reactions (reported in ≥20% of patients) were: KEYTRUDA as a single agent: fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal pain, nausea, and hypothyroidism.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | MSD Europe Belgium SRL |
|---|---|
| Active substance | Pembrolizumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 395 mg |
| Form | oplossing voor injectie |
| Classification | L01FF02 · Cancer treatments and immune-system medicines |
| Route | subcutaan gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | EU/1/15/1024 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.